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Abstract
Background: DLC2, a unique RhoGAP, has been recently identified as a tumor suppressor gene
in hepatocellular carcinoma (HCC). However, the expression of DLC2 protein, and its relationship
with RhoA in clinical hepatocellular carcinoma have not been studied. The aim of this study was to
investigate the DLC2 protein expression and its correlation with expression of RhoA, as well as to
evaluate the prognostic value of DLC2 for HCC patients.
Methods:  Western blot and immunohistochemical staining were employed to detect DLC2
protein expression in 128 HCC specimens. The correlation between DLC2 protein expression and
clinicopathologic outcome, and prognostic value of DLC2 for HCC patients were analyzed.
Results: HCC tissues revealed significantly lower level of DLC2 protein than pericarcinomatous
liver tissues (PCLT). There was significant correlation between underexpression of DLC2 protein
and cell differentiation. Meanwhile, underexpression of DLC2 protein was correlated with
overexression of RhoA. Furthermore, HCC Patients with DLC2-negative expression showed a
significantly poorer prognosis than those with DLC2-positve expression.
Conclusion: Our data strongly suggested that decreased DLC2 expression in HCC correlates
with cell differentiation of HCC and overexpression of RhoA, underexpression of DLC2 is
associated with poor prognosis in HCC patients.
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies in Asia and Africa, especially in China
[1,2]. It is responsible for approximately one million
deaths each year, predominantly in the developing coun-
tries [3]. During the past decades, hepatic resection for
HCC has evolved into a safe procedure with low operative
mortality [4,5]. However, the molecular mechanisms
leading to the development and progression of hepatocel-
lular carcinoma remains unclear. Thus, the delineation of
the mechanisms for hepatocarcinogenesis is of impor-
tance, because it provides novel opportunities for diagno-
sis, prognosis, and therapeutic interventions.
RhoA-GTPase is a member of the Ras-superfamily of small
guanosine triphosphatases (GTPases), which shuttles
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between an inactive GDP-bound state and an active GTP-
bound state and exhibits intrinsic GTPase activities [6].
Activation of Rho protein causes to assembly of the actin-
myosin contractile filaments into focal adhesion com-
plexes that leads to cell polarity and facilitate motility [7].
In human cancers, the alteration of RhoA expression is
involved in tumorigenesis. Indeed, overexpression of
RhoA was detected in several types of cancer including
bladder, testicular, ovarian, colon, breast, and lung [8-11].
Our previous study revealed that overexpression of RhoA
was associated with poor prognosis in hepatocellular car-
cinoma [12]. As activating of RhoGTPases can stimulate
cell proliferation and cell motility, inhibition of the RhoA
activity may suppress the oncogenic and metastatic poten-
tial of tumor cells. Recently, a unique RhoGAP, which
named DLC2 (deleted in liver cancer 2) because of its high
homology to tumor suppressor gene DLC1, has been
identified [13]. DLC2 contains a RhoGAP domain and
exhibits GAP activity on RhoA and Cdc42 in vitro.
Researches show that DLC2 suppresses cell transforma-
tion by means of inhibition of RhoA activity in hepatocel-
lular carcinoma cells [14], meanwhile DLC2 mRNA is
underexpressed in human hepatocellular carcinoma,
which suggested a potential prognostic value of DLC2 for
HCC patients.
However, there has been no available data on the protein
expression of DLC2 in clinical hepatocellular carcinoma.
Does DLC2 protein underexpress in hepatocellular carci-
noma? Or does its expression correlate with clinicopatho-
logical parameters of HCC and expression of RhoA?
Especially, whether DLC2 is a valuable prognostic marker
for HCC patients? In this study, therefore, we examined
the DLC2 protein expression in HCC and evaluated the
relationship between DLC2 expression and clinicopatho-
logical parameters of HCC. Meanwhile, we investigated
the relationship between expression of DLC2 and RhoA;
most importantly, the prognostic value of DLC2 for HCC
patients was also investigated.
Methods
Tissue specimens
The study protocol was approved by the Ethics Committee
of the Central South University. Fresh samples of HCC tis-
sue and pericarcinomatous liver tissue (PCLT, 1 cm away
from the carcinoma) were obtained from 53 (46 male and
7 female) patients with primary hepatocellular carcinoma
who underwent curative hepatectomy at the Third Affili-
ated Hospital of Central South University (CSU) during
2000 to 2003. The specimens were immediately frozen in
liquid nitrogen and stored at -80°C for western blotting.
The median age of these patients was 55 year, ranging
from 19~75 year. All specimens obtained from hepatic
resection were confirmed by pathological examination
and clinicopathological parameters such as tumor diame-
ter, number of tumor node, tumor capsule, histopatho-
logical classification, venous invasion, extrahepatic
metastatic lesion and hepatitis virus infection were
obtained.
Antibody
Because there is no commercial DLC2 antibody at present,
a mouse anti-human DLC2 monoclonal antibody was
developed through ProMab Company. Brief, a 15aa
polypeptide representing a unique epitope was synthe-
sized according to the full-length DLC2 sequence [15],
then the polypeptide was coupled with KLH. After injec-
tion in mouse, immune serum was obtained following
standard techniques. Western blot confirmed the specifi-
city of the antibody for DLC2. The quality control exami-
nation showed that the antibody is valid.
Western blotting
Tissues from HCC and PCLT were lysed in a lysis buffer
(Sigma, St. Louis, MO, USA) and protease-inhibitor
(Promega, Madison, USA). The lysates were centrifuged at
13,000 g for 20 min at 4°C and the supernatants were
stored at -80°C. Extracts equivalent to 50 μg of total pro-
tein were separated by SDS-PAGE gel and were blotted to
polyvinylidene fluoride membrane (Sigma, St. Louis, MO,
USA). After they were blocked in 4% nonfat dry milk in
PBS containing 0.1% Tween-20 for 1 h at room tempera-
ture, the membranes were incubated with primary anti-
body (mouse anti-human DLC2 monoclonal antibody,
ProMab, China, diluted at 1:500) for 1 h at 37°C. After
washing, the membranes were incubated with a 1:5000
dilution of horseradish peroxidase-linked rabbit anti-
mouse antibody (ProMab, China) for 30 mins at 37°C.
Then the membranes were washed and treated with west-
ern blotting luminal reagent (Santa Cruz, California,
USA) to visualize the bands, the results were obtained on
Kodak film and quantified by densitometry (Beckman,
South Pasadena, Canada) [16].
Immunohistochemistry
One hundred and twenty-eight HCC deparaffinized spec-
imens, including the 53 cases of HCC fresh specimens
used for Western blotting, were evaluated for immunohis-
tochemistry. All the specimens were collected from the
Third Affiliated Hospital of Central South University
(CSU) between 1991 and 2003. The clinicopathological
parameters of all the specimens, including tumor diame-
ter, number of tumor node, tumor capsule, histopatho-
logical classification, venous invasion, extrahepatic
metastatic lesion and hepatitis virus infection were
obtained. Follow-up data was obtained following the
operations for all patients; the endpoint of the follow-up
was set at the patients' death. In brief, tissue sections of 4
μm thick were cut and baked at 60°C for 2 h, deparaffin-
ized in xylene and rehydrated through graded ethanol.BMC Cancer 2008, 8:205 http://www.biomedcentral.com/1471-2407/8/205
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Next, 3% hydrogen peroxide was applied to block the
endogenous peroxidases for 20 mins, and the sections
were subjected to heat-induced antigen retrieval in 0.01 M
citrate buffer (PH = 6.0). The sections were incubated with
normal rabbit serum to reduce non-specific binding.
Then, they were incubated at 37°C for 1 h with specific
antibodies (mouse anti-human DLC2 monoclonal anti-
body, ProMab, China) used at a 1:50 dilution. The second
antibody was applied for 45 min at 37°C. The Streptavi-
din-biotin-peroxidase complex (SABC) tertiary system
(Boster, Wuhan, China) was used according to the manu-
facturer's instruction for 20 min at room temperature. The
tissues were visualized by applying 3, 3-diaminobenzi-
dine tetrahydrochloride (DAB) for 3 min. Sections were
counterstained using haematoxylin, dehydrated through
gradient alcohols and mounted for viewing. Negative con-
trols were done by omitting the primary antibody,
whereas, HCC specimens of high DLC2 expression con-
firmed by Western blotting were used as positive controls.
The intensity of cytoplasmic staining was scored as 0 to 3+
by comparison to the positive controls. DLC2-negative
expressions were devoid of any cytoplasmic staining or
contained faint, equivocal staining (scores 0 and 1+) [12].
Statistical analysis
Statistical analysis was performed using the SPSS (version
11.0, Chicago, IL). A Student's t test was used to analyze
the expression of DLC2 between HCC and PCLT. Spear-
man's correlation coefficient was used to examine the
relationship between expression of DLC2 and RhoA. The
Mann-Whitney U test and chi-square test were monitored
to analyze the correlation between the expression of
DLC2 and clinicopathological variables. Post-operative
overall survival was analyzed by the Log-rank test. Differ-
ences were considered significant when P < 0.05.
Results
Expression of DLC2 protein in HCC and PCLT
Expression of DLC2 protein was detected in all HCC and
PCLT. The relative expression of DLC2 protein was 0.40 ±
0.06 in HCC and 0.57 ± 0.08 in PCLT respectively. HCC
tissues revealed significantly lower levels of DLC2 protein
than PCLT (P = 0.02) (Figure 1).
Correlation between DLC2 expression levels and 
clinicopathological parameters of HCC
The distribution pattern of DLC2 was determined by
dividing the expression levels of DLC2 protein in sub-
groups by clinicopathological parameters. HCC with poor
cell differentiation showed a lower expression level of
DLC2 protein than those with well cell differentiation.
There were no significant associations between expression
of DLC2 gene and other clinicopathological parameters
such as sex, hepatitis virus infection, liver cirrhosis, tumor
size and capsular condition, venous invasion and nodular
number (Table 1). The same result was observed based on
the correlation between immunohistochemical study and
clinicopathological parameters of 128 cases of HCC spec-
imen (Table 2).
Correlation between DLC2 expression and RhoA 
expression
The protein expressions of DLC2 and RhoA were exam-
ined simultaneously. The protein expressions of DLC2
and RhoA showed strongly negative correlation. (correla-
tion coefficient = -0.447, P = 0.01) (Figure 2).
Correlation between DLC2 expression and prognosis of 
HCC
To further investigate the correlation between DLC2
expression level and prognosis, HCCs were divided into
the DLC2 negative expression group (immunohistochem-
istry score 0 and 1+; n = 95) and DLC2 positive expression
group (immunohistochemistry scores 2+ and 3+; n = 33).
DLC2 expression level and the prognosis of HCC patients
were analyzed by Kaplan-Meier method. The result
showed the mean overall survival of patients with DLC2-
Expression of DLC2 protein Figure 1
Expression of DLC2 protein. Expression of DLC2 pro-
tein was detected in 53 cases of HCC fresh specimens using 
western blot, HCC tissues revealed significantly lower levels 
of DLC2 protein than PCLT. P = 0.02.BMC Cancer 2008, 8:205 http://www.biomedcentral.com/1471-2407/8/205
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negative expression (414 days) was significantly lower
than those of patients with DLC2-positive expression
(697 days, P = 0.003). HCC Patients with DLC2-negative
expression revealed significantly poorer prognosis than
those with DLC2-positive expression (Figure 3).
Discussion
Although DLC2 has been identified as a tumor suppressor
gene in HCC, the expression of DLC2 protein, especially
the relationship with RhoA in clinical hepatocellular car-
cinoma has not been studied. The previous study demon-
strated that the mRNA expression of DLC2 was
significantly lower in HCC than in PCLT [13]. In human
neoplasms, it has been reported that DLC2 was down-reg-
ulated in lung, ovarian, renal, breast, uterine, gastric,
colon and rectal tumor [17]. Also, underexpression of
DLC2 was confirmed to be help for invasion and migra-
tion of hepatocellular carcinoma cells [14]. Consistent
with previous documents, our present study shows that
DLC2, on protein level, is down-regulated in HCC, which
indicates that DLC2 may participate in hepatocarcinogen-
esis.
To investigate how DLC2 affects hepatocarcinogenesis, we
evaluated the correlation between DLC2 expression level
and clinicopathological parameters of HCC. Our results
show that the expression of DLC2 protein is lower in HCC
than PCLT, which is more frequently associated with cell
differentiation. This result is consistent with the role of
DLC2 as a tumor suppressor gene in HCC. As previous
study indicated that DLC2 encodes a RhoGAP protein
with growth suppressor function in hepatocellular carci-
noma, we hypothesized that DLC2 may down-regulate
expression of RhoA. Thus, the protein expression of DLC2
and RhoA were examined simultaneously in human hepa-
tocellular carcinoma. Anticipatively, the protein expres-
sion of DLC2 and RhoA showed strongly negative
correlation, which was consistent with the hypothesis that
DLC2 suppresses hepatocarcinogenesis by means of inhi-
Table 1: The relationship between expression level of DLC2 
protein and clinicopathological parameters for 53 cases of HCC 
specimen.
Clinicopathological 
parameters
No. of patients Expression of 
DLC2 protein
P value
Sex
Male 46 0.41 ± 0.08 0.49
Female 7 0.39 ± 0.06
Liver cirrhosis
Present 32 0.39 ± 0.04 0.78
Absent 21 0.40 ± 0.07
Hepatitis virus infection
Present 47 0.41 ± 0.04 0.72
Absent 6 0.40 ± 0.05
Capsule formation
Present 27 0.40 ± 0.04 0.63
Absent 26 0.39 ± 0.06
Tumor nodule
≥ 2 35 0.42 ± 0.10 0.23
< 2 18 0.39 ± 0.06
Cell differentiation*
I ~ II 24 0.42 ± 0.06 0.02**
III ~ IV 29 0.38 ± 0.05
Vein invasion
Present 26 0.41 ± 0.09 0.13
Absent 27 0.39 ± 0.13
Extrahepatic metastasis
Present 11 0.40 ± 0.06 0.34
Absent 42 0.39 ± 0.08
Tumor size
> 5 cm 38 0.41 ± 0.06 0.57
≤ 5 cm 15 0.40 ± 0.09
*classified by Edmondson-Steiner grade
**by Mann-Whitney U test, P < 0.05
Table 2: The correlation between immunohistochemical studies 
and clinicopathological parameters for 128 cases of HCC 
specimens.
Clinicopathological 
parameters
No. of 
patients
DLC2 expression P value
Positive Negative
Sex
Male 116 30 86 0.95
Female 12 3 9
Liver cirrhosis
Present 80 20 60 0.79
Absent 48 13 35
Hepatitis virus infection
Present 107 25 82 0.15
Absent 21 8 13
Capsule formation
Present 71 18 53 0.91
Absent 57 15 42
Tumor nodule
≥ 2 82 19 63 0.36
< 2 46 14 32
Cell differentiation*
I ~ II 52 20 32 0.01**
III ~ IV 76 13 63
Vein invasion
Present 54 16 38 0.39
Absent 74 17 57
Extrahepatic metastasis
Present 28 9 19 0.38
Absent 100 24 76
Tumor size
> 5 cm 70 18 52 0.98
≤ 5 cm 58 15 43
*classified by Edmondson-Steiner grade
**by Chi-square test, P < 0.05BMC Cancer 2008, 8:205 http://www.biomedcentral.com/1471-2407/8/205
Page 5 of 7
(page number not for citation purposes)
bition of RhoA activity [14]. However, there was no evi-
dence to confirm the direct relationship between DLC2
and RhoA. The increase in RhoA protein in HCC samples
observed in our study may not be a direct result of reduced
DLC2 expression, but could be due to cancer-related alter-
ations in upstream factors that regulate the two genes.
Therefore, the further investigation is anticipated.
In our study, the underexpression of DLC2 correlates with
cell differentiation, which suggests a possibility that DLC2
expression could be used as a potential prognostic marker
for HCC patients. To explore this possibility, anti-DLC2
immunohistochemical staining was performed on 128
cases of HCC specimens. Because of lower detection sen-
sitivity of the immunohistochemistry method, some of
the 128 cases of HCC show negative staining of DLC2,
notwithstanding DLC2 protein is detected in all 53 cases
of HCC with western blotting. Nevertheless, when we
divide the total cases of HCC into either DLC2 positive or
negative group, the DLC2-positive HCC patients in gen-
eral had a better prognosis than the DLC2-negative HCC
patients. On the whole, our results strongly suggest that
decreased DLC2 expression in HCC correlates with a poor
prognosis for HCC patients.
Conclusion
Our results strongly suggest that decreased DLC2 expres-
sion in HCC correlates with cell differentiation of HCC
and overexpression of RhoA, underexpression of DLC2 in
HCC indicates a poor prognosis for HCC patients.
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Correlation between DLC2 protein expression and RhoA protein expression Figure 2
Correlation between DLC2 protein expression and RhoA protein expression. Correlation between DLC2 protein 
expression and RhoA protein expression was evaluated by Spearman's correlation coefficient. DLC2 protein levels were nega-
tive correlated with the levels of RhoA protein in HCC with adjusted -0.447 and two-tailed probability, n = 53, P = 0.01.BMC Cancer 2008, 8:205 http://www.biomedcentral.com/1471-2407/8/205
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Correlation between DLC2 expression and prognosis of HCC Figure 3
Correlation between DLC2 expression and prognosis of HCC. Expression of DLC2 protein was detected in 128 cases 
of HCC deparaffinized specimens by immunohistochemistry method. HCC specimen of DLC2 high expression confirmed by 
Western blotting was used as positive controls (a), whereas negative controls were done by omitting the primary antibody (b). 
The representative positive expression of DLC2 (c) and negative expression of DLC2 (d) in HCC specimens were presented. 
Kaplan-Meier survival curves for DLC2-positive expression group (n = 33) and DLC2-negative expression group (n = 95) based 
on results of immunohistochemistry (e). HCC patients with DLC2-negative expression revealed significant poor prognosis than 
those with DLC2-positive expression, Log-rank test, P = 0.003.Publish with BioMed Central    and   every 
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